Gastroesophageal reflux disease
Conditions
Interventions
10 mg of sodium rabeprazole administered orally once daily from 2 to 4 weeks
Sponsors
Heiwadai clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A patient is eligible for the study if all of the following criteria are met: 1) Age 20 years or older 2) Patients with more than 8 scores in the Frequency scale for Symptoms of GERD (F-scale questionnaires) 3) Patient with at least 2 weeks washout period from the previous treatment by Proton pump inhibitors and Histamine H2-receptor antagonists
Exclusion criteria
Exclusion criteria: A patient is excluded from the study if any of the following criteria are met: 1) Patients with a history of hypersensitivity to any ingredients of sodium rabeprazole 2) Patients taking atazanavir sulfate or rilpivirine hydrochloride 3) Patients with serious hepatic function disorder 4) Elderly patients (Age 80 years and older) 5) Patients who were judged to be inappropriate for participation in this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Change rate of average numerical rating scale (NRS) of sleep quality between a pre-dose and a post-dose of 2-4 weeks after administration 2)Fluctuation of scores in sleep dysfunction questionnaires between a pre-dose and a post-dose of 2-4 weeks after administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Fluctuation of scores in F-scale questionnaires between a pre-dose and a post-dose of 2-4 weeks after administration | — |
Countries
Japan
Contacts
Public ContactMotoyasu chibai
Heiwadai clinic Surgery
Outcome results
None listed